Taiwan’s first Taiwan Stock Exchange (TWSE)-listed venture capital firm, Diamond Biofund, has proudly announced a substantial investment of US$4 million in SYNCELL Inc. This investment is intended to facilitate the pilot production of cutting-edge Spatial Biology instruments in Taiwan, preparing for global market entry.

Founded by Dr. Chung-Chi Liao, SYNCELL Inc., a spin-off startup company of Academia Sinica, is known for its groundbreaking spatial transcriptomics and spatial proteomics technologies. These innovations have led to the creation of MicroscoopTM, an unrivaled technology platform that seamlessly integrates microscopes to capture elusive proteins and nucleic acids with pinpoint accuracy. This remarkable platform hosts extensive applications in cell and clinical biopsy analyses, utilizing AI-driven recognition technology and an exclusive “light-curing reagent” to isolate proteins and nucleic acids within specific cellular structures. This results in the ability to detect previously unknown, clinically significant proteins, while also overcoming existing challenges in spatial transcriptomics and spatial proteomics technologies. This revolutionary platform has potential applications in new drug development, pharmaco-pathological research, and drug target exploration.

Dr. Liao highlighted the pivotal role SYNCELL Inc. plays in global competition, aided by an impressive patent portfolio and swift development of MicroscoopTM products within just two years of its inception. Each unit’s price commands hundreds of thousands of US dollars, and the company has secured orders from prestigious institutions like the Mayo Clinic, ranked as the top one of the World’s Best Hospitals 2023, and the New York Structural Biology Center (NYSBC). Additionally, more than ten entities have expressed keen interest in purchasing, a clear testament to the burgeoning market demand and the innovative edge of MicroscoopTM.

SYNCELL Inc. is poised to establish a marketing and sales hub in Boston, USA, paving the way for collaboration with strategic partners in sales and licensing efforts. It is on track to become an attractive acquisition target for major global spatial biology and laboratory equipment manufacturers, with the possibility of going public on NASDAQ or Taiwan’s capital market in the near future.

William Lu, Chairman of Diamond Biofund, emphasized the rapid growth of spatial biology as a field of great interest to leading international journals such as Nature, Science, and Cell. SYNCELL Inc., for its remarkable two-year journey from R&D to mass production set for 2024, positions itself to lead the global arena in spatial transcriptomics and spatial proteomics technologies.

Notably, SYNCELL Inc. recently completed an US$8 million fundraising, with US$4 million from Diamond Biofund towards their visionary mission.

About Diamond Biofund

Diamond Biofund is the first Taiwan Stock Exchange (TWSE)-listed evergreen biotech venture capital firm in Taiwan. With its mission to “Nurture Innovation for Better Quality of Life,” the firm specializes in biotechnology and medical investments. Diamond Biofund’s focus extends to globally competitive prospects, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. In addition to financial investment, Diamond Biofund provides invaluable support to portfolio companies in diverse areas, such as corporate governance, R&D, clinical implementation, business development, and capital market integration, all aimed at driving portfolio growth and delivering investment returns to shareholders.

Press Contact: Patricia Chou
Phone: +886-2-2703-1068